HRS-3738 vs Pomalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon (CRBN) · full Multiple Myeloma pipeline
HRS-3738
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05363800 (registry estimate)
No aligned efficacy figure on record for this race.
Pomalidomide
Marketed by Bristol-Myers Squibb and partners
NCT01311687 · Phase 3 · completed
This was a large, randomized 2:1 active-controlled trial involving 302 participants assigned to pomalidomide plus low-dose dexamethasone and 153 assigned to high-dose dexamethasone, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, progression-free survival, was met: median PFS was 15.7 versus 8.0 weeks, with HR 0.45 (95% CI 0.35–0.59; p<0.001), supporting a moderate evidence grade.
Next expected readout: November 2026 · NCT04973605 (registry estimate)
Reported efficacy
Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23% (not_applicable)
Result source: NCT01324947
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRS-3738 | Pomalidomide |
|---|---|---|
| PFS, median | —Not reported | 3.6 vs 1.9vs DexamethasoneNCT0131168731 other results
|
| OS, median | —Not reported | 12.5 vs 8.1vs DexamethasoneNCT0131168713 other results
|
| ORR | —Not reported | 23%bNCT0132494717 other results
|
| VGPR or better | —Not reported | 31.8% vs 8.5%vs Pomalidomide + DexamethasoneNCT02990338 |
| MRD negativity | —Not reported | —Not posted · NCT03651128 |
PFS, median
- HRS-3738
- —Not reported
- Pomalidomide
- 3.6 vs 1.9vs DexamethasoneNCT01311687
31 other results
- 3.7 vs 1.9 NCT01311687
- 11.5 vs 6.5 NCT02990338
- 11.2 vs 7.1 NCT01734928
- 8.4 vs 7.3 NCT02726581
- 7.5 vs 3.7 NCT02990338
- 4.6 NCT01712789
- 3.7 NCT01324947
- 10.3 vs 4.7 NCT02654132
- 3.8 NCT00833833
- 2.5 NCT00833833
- 11.1 NCT02612779
- 13 NCT00558896
- 4.3 NCT00558896
- 5 NCT00558896
- 6.4 NCT00558896
- 3.3 NCT00558896
- 7.7 NCT00558896
- 14.1 NCT00558896
- 4.4 NCT02011113
- 7.4 NCT02011113
- 6.2 NCT01592370
- 6.9 NCT01592370
- 3.0 NCT01592370
- 17.5 NCT02939183
- 8.4 NCT01421186
- 15.9 NCT01421186
- 1.9 NCT02612779
- 26.7 NCT01421186
- 2.1 NCT01421186
- 6.7 NCT03269136
- 14.2 NCT02939183
OS, median
- HRS-3738
- —Not reported
- Pomalidomide
- 12.5 vs 8.1vs DexamethasoneNCT01311687
13 other results
- 12.9 vs 8.2 NCT01311687
- 24.6 vs 17.7 NCT02990338
- 35.6 vs 31.6 NCT01734928
- 24.9 vs 21.4 NCT02726581
- 11.9 NCT01712789
- 7.8 NCT01324947
- 29.8 vs 17.4 NCT02654132
- 14.4 NCT00833833
- 13.7 NCT00833833
- 41.2 NCT02612779
- 52.6 NCT01592370
- 30.4 NCT01592370
- 14.9 NCT01592370
ORR
- HRS-3738
- —Not reported
- Pomalidomide
- 23%bNCT01324947
17 other results
- 23.5% vs 3.9% NCT01311687
- 22.2% vs 3.3% NCT01311687
- 60.4% vs 35.3% NCT02990338
- 48% vs 54.9% NCT02726581
- 33.4% NCT01712789
- 20.3% NCT01324947
- 20% NCT01319422
- 15.8% NCT01319422
- 83% NCT03439280
- 87.5% NCT02939183
- 60% NCT02939183
- 85.7% NCT02939183
- 60% NCT02939183
- 0% NCT02939183
- 50% NCT03828292
- 77.8% NCT03269136
- 33.3% NCT02939183
VGPR or better
- HRS-3738
- —Not reported
- Pomalidomide
- 31.8% vs 8.5%vs Pomalidomide + DexamethasoneNCT02990338
MRD negativity
- HRS-3738
- —Not reported
- Pomalidomide
- —Not posted · NCT03651128
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-3738: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HRS-3738: 0 of 4 rows · Pomalidomide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pomalidomide |
|---|---|
| Dropout rate | 0%a NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more resultsn/a: no completion milestone NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 64.3%4 mg NCT00833833 · Phase 1/2 60%5 mg NCT00833833 · Phase 1/2 62.5%3 mg NCT00833833 · Phase 1/2 66.7%2 mg NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide (Pom + Dex O NCT00833833 · Phase 1/2 · combination —Phase 2: Pomalidomide (Pom Only) NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide + Dexamethas NCT00833833 · Phase 1/2 · combination —Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination —Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 1.1%Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 4%Arm A: N-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination —Arm B: NE-Pd Crossover NCT02726581 · Phase 3 · registry result, not featured evidence · combination 0%Arm C: NE-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT01712789 · Phase 3 · registry result, not featured evidence · combination 0% NCT02654132 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneEN Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneEPd Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination 14.3%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 34.3%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 20.6%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 72.7%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 38.3%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 35%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 43.3%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT02011113 · Phase 2 · registry result, not featured evidence · combination 0%4 mg/d on 21 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence 5%2 mg/d on 28 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT01177735 · Phase 2 · registry result, not featured evidence —Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 83.3%Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 85.7%Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 83.7%Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 72.7%Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 38.5%Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 100%Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 99%Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%300 mg NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2 0%Part B: MOR03087 Weekly Dose Escal NCT01421186 · Phase 1/2 · registry result, not featured evidence 0%Part C: MOR03087 Plus Dexamethason NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 0%Part D: MOR03087 Plus Pomalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 0%Part E: MOR03087 Plus Lenalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone NCT03269136 · Phase 1 · registry result, not featured evidence · combination 37.5%IR 250 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 63.6%IR 225 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 40%GR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 22.2%IR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 60%GR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 33.3%IR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more results9.5% NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 14.3%4 mg NCT00833833 · Phase 1/2 10%5 mg NCT00833833 · Phase 1/2 0%3 mg NCT00833833 · Phase 1/2 16.7%2 mg NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide (Pom + Dex O NCT00833833 · Phase 1/2 · combination —Phase 2: Pomalidomide (Pom Only) NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide + Dexamethas NCT00833833 · Phase 1/2 · combination —Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination —Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Arm A: N-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination —Arm B: NE-Pd Crossover NCT02726581 · Phase 3 · registry result, not featured evidence · combination —Arm C: NE-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination 7.6% NCT01712789 · Phase 3 · registry result, not featured evidence · combination — NCT02654132 · Phase 2 · registry result, not featured evidence · combination 0%EN Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination 7.4%EPd Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination 2.9%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 8.6%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 2.9%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 9.1%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 6.7%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 1.7%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 8.3%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 11.1% NCT02011113 · Phase 2 · registry result, not featured evidence · combination —4 mg/d on 21 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence —2 mg/d on 28 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence — NCT01177735 · Phase 2 · registry result, not featured evidence —Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy —300 mg NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2 —Part B: MOR03087 Weekly Dose Escal NCT01421186 · Phase 1/2 · registry result, not featured evidence —Part C: MOR03087 Plus Dexamethason NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination —Part D: MOR03087 Plus Pomalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination —Part E: MOR03087 Plus Lenalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 11.1% NCT03269136 · Phase 1 · registry result, not featured evidence · combination 0%IR 250 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 9.1%IR 225 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 0%GR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 0%IR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 20%GR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 0%IR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 65%a NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more results71.2% NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 57.1%4 mg NCT00833833 · Phase 1/2 40%5 mg NCT00833833 · Phase 1/2 50%3 mg NCT00833833 · Phase 1/2 50%2 mg NCT00833833 · Phase 1/2 —Phase 2: Pomalidomide NCT00833833 · Phase 1/2 47.5%Phase 2: Pomalidomide (Pom + Dex O NCT00833833 · Phase 1/2 · combination 46.7%Phase 2: Pomalidomide (Pom Only) NCT00833833 · Phase 1/2 61.6%Phase 2: Pomalidomide + Dexamethas NCT00833833 · Phase 1/2 · combination 42.9%Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination 54.2%Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination 73.7% NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 63.7%Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 72.2%Arm A: N-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination 62.5%Arm B: NE-Pd Crossover NCT02726581 · Phase 3 · registry result, not featured evidence · combination 75%Arm C: NE-Pd NCT02726581 · Phase 3 · registry result, not featured evidence · combination 66.3% NCT01712789 · Phase 3 · registry result, not featured evidence · combination 70% NCT02654132 · Phase 2 · registry result, not featured evidence · combination 50%EN Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination 57.4%EPd Cohort NCT02612779 · Phase 2 · registry result, not featured evidence · combination 42.9%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 31.4%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 32.4%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 54.5%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 35%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 36.7%Low Dose NCT00558896 · Phase 2 · registry result, not featured evidence 26.9%High Dose NCT00558896 · Phase 2 · registry result, not featured evidence 44.4% NCT02011113 · Phase 2 · registry result, not featured evidence · combination 55%4 mg/d on 21 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence 36.8%2 mg/d on 28 Days/28 Day Cycle NCT01319422 · Phase 2 · registry result, not featured evidence 8.5% NCT01177735 · Phase 2 · registry result, not featured evidence 50%Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 100%Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 36.6%Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 40.9%Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 60%Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 47.2%Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 47.6%Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%300 mg NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2 100%Part B: MOR03087 Weekly Dose Escal NCT01421186 · Phase 1/2 · registry result, not featured evidence 38.9%Part C: MOR03087 Plus Dexamethason NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 95.2%Part D: MOR03087 Plus Pomalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 82.4%Part E: MOR03087 Plus Lenalidomide NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 25%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 0%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 88.9% NCT03269136 · Phase 1 · registry result, not featured evidence · combination 50%IR 250 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 30%IR 225 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 100%GR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 75%IR 200 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 100%GR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination 50%IR 150 mg/day NCT02939183 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a anaemia 53% neutropenia 51.7% fatigue 34.3% NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 show 51 more resultsanaemia 49.3% neutropenia 47.9% constipation 21.9% NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 fatigue 57.1% neutropenia 57.1% lymphopenia 42.9% NCT03180736 · Phase 3 · registry result, not featured evidence · combination neutropenia 72.5% anaemia 38.7% thrombocytopenia 33.8% NCT03180736 · Phase 3 · registry result, not featured evidence · combination neutropenia 50.7% upper respiratory tract infection 34.9% infusion related reaction 34.2% NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 neutropenia 54% peripheral sensory neuropathy 48.2% thrombocytopenia 39.6% NCT01734928 · Phase 3 · registry result, not featured evidence · combination fatigue 47.2% anaemia 36.1% neutropenia 33.3% NCT02726581 · Phase 3 · registry result, not featured evidence · combination fatigue 75% anaemia 25% asthenia 25% NCT02726581 · Phase 3 · registry result, not featured evidence · combination pyrexia 58.3% anaemia 45.8% fatigue 41.7% NCT02726581 · Phase 3 · registry result, not featured evidence · combination neutropenia 56.5% anaemia 48.4% thrombocytopenia 34.9% NCT01712789 · Phase 3 · registry result, not featured evidence · combination anaemia 28.3% neutropenia 26.7% diarrhoea 25% NCT02654132 · Phase 2 · registry result, not featured evidence · combination anaemia 33.3% decreased appetite 33.3% infusion related reaction 33.3% NCT02612779 · Phase 2 · registry result, not featured evidence · combination fatigue 54.4% upper respiratory tract infection 36.8% diarrhoea 35.3% NCT02612779 · Phase 2 · registry result, not featured evidence · combination Low Dose hemoglobin decreased 97.1% fatigue 88.6% platelet count decreased 85.7% NCT00558896 · Phase 2 · registry result, not featured evidence High Dose hemoglobin decreased 97.1% fatigue 91.4% leukocyte count decreased 88.6% NCT00558896 · Phase 2 · registry result, not featured evidence Low Dose hemoglobin decreased 100% fatigue 94.1% leukocyte count decreased 79.4% NCT00558896 · Phase 2 · registry result, not featured evidence Low Dose fatigue 97% hemoglobin decreased 93.9% peripheral sensory neuropathy 87.9% NCT00558896 · Phase 2 · registry result, not featured evidence High Dose fatigue 93.3% hemoglobin decreased 91.7% leukocyte count decreased 90% NCT00558896 · Phase 2 · registry result, not featured evidence Low Dose hemoglobin decreased 95% fatigue 93.3% neutrophil count decreased 80% NCT00558896 · Phase 2 · registry result, not featured evidence High Dose hemoglobin decreased 96.6% fatigue 93.3% leukocyte count decreased 86.6% NCT00558896 · Phase 2 · registry result, not featured evidence neutropenia 72.2% anaemia 47.2% thrombocytopenia 44.4% NCT02011113 · Phase 2 · registry result, not featured evidence · combination 4 mg/d on 21 Days/28 Day Cycle leukopenia 75% fatigue 60% anemia 50% NCT01319422 · Phase 2 · registry result, not featured evidence 2 mg/d on 28 Days/28 Day Cycle fatigue 78.9% leukopenia 63.2% anemia 31.6% NCT01319422 · Phase 2 · registry result, not featured evidence anemia 100% blood/bone marrow 100% leukopenia 100% NCT01177735 · Phase 2 · registry result, not featured evidence anaemia 50% arthralgia 50% cough 50% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 80% diarrhoea 80% hypomagnesaemia 80% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 24.4% infusion related reaction 24.4% neutropenia 22% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 18.2% diarrhoea 18.2% infusion related reaction 18.2% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 46.2% pyrexia 38.5% cough 33.8% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 41.7% diarrhoea 29.2% anaemia 25% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 43.8% cough 27.6% diarrhoea 26.7% NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 300 mg neutropenia 50% neutrophil count decreased 50% constipation 33.3% NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2 leukopenia 100% neutropenia 75% cough 50% NCT01421186 · Phase 1/2 · registry result, not featured evidence plasma cell myeloma 66.7% nasopharyngitis 50% leukopenia 44.4% NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination neutropenia 90.5% leukopenia 81% lymphopenia 66.7% NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination leukopenia 88.2% lymphopenia 76.5% neutropenia 70.6% NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex constipation 50% neutrophil count decreased 50% oedema peripheral 50% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex abdominal pain upper 0% abnormal faeces 0% alanine aminotransferase increased 0% NCT03828292 · Phase 1 · registry result, not featured evidence · combination fatigue 77.8% neutropenia 77.8% diarrhoea 66.7% NCT03269136 · Phase 1 · registry result, not featured evidence · combination IR 250 mg/day diarrhoea 100% nausea 100% vomiting 87.5% NCT02939183 · Phase 1 · registry result, not featured evidence · combination IR 225 mg/day diarrhoea 80% nausea 80% vomiting 70% NCT02939183 · Phase 1 · registry result, not featured evidence · combination GR 200 mg/day diarrhoea 80% back pain 60% constipation 60% NCT02939183 · Phase 1 · registry result, not featured evidence · combination IR 200 mg/day nausea 75% vomiting 75% diarrhoea 62.5% NCT02939183 · Phase 1 · registry result, not featured evidence · combination GR 150 mg/day fatigue 75% nausea 75% cough 50% NCT02939183 · Phase 1 · registry result, not featured evidence · combination IR 150 mg/day anaemia 75% diarrhoea 75% nausea 75% NCT02939183 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 51 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pomalidomide
show 6 more results
show 6 more results
show 3 more results
show 1 more result
show 2 more results
show 3 more results
show 13 more results
show 28 more results
show 5 more results
show 24 more results
show 9 more results
show 6 more results
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-3738's landscape · Pomalidomide's landscape